shares of arcturus therapeutics holdings fell after the companys loss widened more than expected in the second quarter the stock was down 79 to 2932 in afterhours trading shares have risen 88 so far this year as of mondays close the san diegobased rna medicines company reported a secondquarter loss of 5255 million or 198 a share compared with 2156 million or 82 cents a share a year earlier analysts polled by factset expected a loss of 134 a share the companys revenue sank to 105 million from 271 million a year ago arcturus said the decline was largely attributable to the termination of an agreement with vinbiocare and lower revenue from the companys agreement with the israeli ministry of health